Synthesis, Structure, and Pharmacological Screening of 2,7-Naphthyridine Derivatives

• Autorzy: Wagner E. , Wójcicka A. , Bryndal I. , Lis T.
• Języki publikacji: EN

Abstrakty

EN

An attempt to rearrange pyrrolo[3,4-c]pyridine-1,3-diones to the 2,7-naphthyridine ring under the conditions, described in only one report [1], gave compounds 7-9, but did not yield the expected 2,7- or 2,6-naphthyridine isomers. Important for the synthesis of the naphthyridine ring from pyrrolo[3,4-c]pyridine was that, of the two possible isomers, only 2,7- not 2,6-naphthyridine was obtained. Ethyl (4-R'-1,3- dioxo- 6-phenyl-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)acetate (5, 6, 10) treated with sodium ethoxide was rearranged by the Claisen-Dieckmann reaction to ethyl 4-hydroxy-8-R'-1-oxo-6-phenyl-1,2-dihydro-2,7-naphthyridine-3-carboxylate (13, 14), where R' = methyl or ethoxy. The structures of the new compounds were confirmed by elemental analysis and NMR and IR spectra. The structure of 14 was also determined by X-ray crystallography to prove the presence of 2,7-naphthyridine isomer. The in vitro anticancer activities of the final 2,7-naphthyridines were tested at the US NCI (Bethesda, MD). Compound 13 exhibited cytostatic activity in vitro.

Słowa kluczowe

EN

pyrrolo[3,4-c]pyridines; 6-phenyl-2,7-naphthyridine-3-carboxylate derivatives; anticancer activity

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2009
• Tom: Vol. 83, nr 2
• Strony: 207--215
• Opis fizyczny: Bibliogr. 34 poz., rys.

Twórcy

autor

Wagner E.

autor

Wójcicka A.

autor

Bryndal I.

autor

Lis T.

• Department of Technology of Drugs, Wroclaw Medical University, pl. Nankiera 1, 50-140 Wrocław, Poland,

Bibliografia

• 1. Gabriel S. and Colman J., Ber. Dtsch. Chem. Ges., 35, 1358 (1902).
• 2. Guillier F.,Nivoliers F.,Godard A.,Marsais F.and Quegiuner G.,J. Heterocycl. Chem., 36,1157(1999).
• 3. Ding Q. and Lown J.W., J. Org. Chem., 64, 7965 (1999).
• 4. Magnier E. and Langlois Y., Tetrahedron Lett., 39, 837 (1998).
• 5. Urban D., Duval E. and Langlois Y, Tetrahedron Lett., 41, 9251 (2000).
• 6. Smith K.L. and Ray P.S., Heterocycl, 45(1), 11 (1997).
• 7. Scherico Ltd., Belg. 835,770, 20 (1976); C. A. 87, 2325It, (1977).
• 8. Muhammad L, Dunbar D.C., Takamatsu S., Walker L.A. and Clark A.M., J. Nat. Prod., 64(5), 559 (2001).
• 9. Clifford J., McKay C. and Porter J.R., PCT. Int. Appl WO 2002042264, UK; C. A. 136,401746 (2002).
• 10. Shmitz F.J., Agrawal S.K., Gunasekera S.P., Schmidt P.J. and Shoorley J.N., J. Am. Chem. Soc., 105, 4835 (1983).
• 11. Honda H., Konno F., Koda T., Matsuda H. and Katori T, Jpn. Kokai Tokkyo Koho JP, 63,239,285,05 (1988); C. A. 110, 135223k (1989).
• 12. McCarthy P. J., Pitts T.P., Gunawardana G.P., Kelly-Borges M. and Pomponi S .A., J. Nat. Prod., 55,1664 (1992).
• 13. Gorlitzer K., Bode M. and Jones P.G., Pharmazie, 62(1), 15 (2007).
• 14. Mochida H., Noto T, Inoue H. and Yano K., Eur. J. Pharmacol, 485(1-3), 283 (2004).
• 15. Nadsukari H., Ishimaru T. and Doi T., Jpn. Kokai Tokkyo Koho JP, 08,337,583,24 (1996); C. A. 126, 1574954h(1997).
• 16. Ikeura Y, Tanaka T, Kiyota Y, Mirimato S., Ogino M., Ishimaru T., Karno L, Doi T. and Nastugari H., Chem. Pharm. Bull., 45(10), 1642 (1997).
• 17. Gross H., Goeger D.E., Hills P, Mooberr S.L., Ballantine D.L., Murray T.F., Valeriote F. A. and Gerwick W.H., J. Nat. Prod., 69(4), 640 (2006).
• 18. Palfreyman M.N. and Wooldridge K.R.H., J. Chem. Soc. Perkin Trans., l, 57 (1974).
• 19. Molina P., Lorenzo A. and Aller E., Tetrahedron, 48(22), 4601 (1992).
• 20. Tverdokhlebov A.V., Resnyanska E.V., Tolmachev A.A. and Zavada A.V., Monatsh. Chem., 134,1045 (2003).
• 21. Krivpalov V.P., Sedova V.F. and Shkurko O.P., Russ. Chem. Bull., 52(11), 2440 (2003).
• 22. Vedensky V.Y., Ivanov Y.Y., Kysil Y, Williams C., Tkachenko S., Kiselyov A., Khavat A.V. and Ivachtchenko A.V, Tetrahedron Lett., 46, 3953 (2005).
• 23. Sheffield DJ. and Wooldridge K.R.H., J. Chem. Soc. Perkin Trans., l, 2506 (1972).
• 24. Bennasar M., Roca T., Zulaica E. and Monerris M., Tetrahedron, 60, 2063 (2004).
• 25. Oka Y, Itoh K., Miyake A., Tada N., Omura K., Tomimoto M. and Yurugi S., Chem. Pharm. Bull., 23(10), 2306 (1975).
• 26. Sucharda E., Ber., 58, 1727 (1925).
• 27. Mumm O. and Neumann R., Ber., 59, 1618 (1926).
• 28. Liu H. Ko S., Josien H. and Curran D. P., Tetrahedron Lett., 36, 8917 (1995).
• 29. Monks A., Scudiero D.A., Skehan P., Shoemarker R.H., Paul K.D., Vistica D.T. et al.,J. Natl. Cancer Inst, 83, 757 (1991).
• 30. Shoemarker R.H, Nat. Rev. Cancer, 6, 813 (2006).
• 31. Bernstein J., Davis R.E., Shimoni L. and Chang N.L., Angew. Chem. Int. Ed. Engl., 34, 1555 (1995)
• 32. Oxford Diffraction Ltd. (l 995-2003). Xcalibur PX Software - CryAlis CCD and CrysAlis RED Version 171. Oxford Diffraction Poland, Wrocław, Poland.
• 33.  Sheldrick G.M., SHELXS-97. Program for the solution of crystal structures. University of Göttingen Germany, (1997).
• 34.  Sheldrick G.M., SHELXL-97. Program for the refmement of crystal structures. University of Göttingen'Germany, (1997).